Strategies for Biology- and Molecular-Based Treatment of Myelodysplastic Syndromes

Publisher： Bentham Science Publishers

E-ISSN： 1873-5592|6|6|713-725

ISSN： 1389-4501

Source： Current Drug Targets, Vol.6, Iss.6, 2005-09, pp. : 713-725

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lenalidomide for Treatment of Myelodysplastic Syndromes

By  

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3198-3203

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial [Hot Topic:Strategies for Molecular-Based Treatment of Hematological Malignancies (Guest Editor: Per Ole Iversen)]

By  

Current Drug Targets, Vol. 6, Iss. 6, 2005-09 ,pp. : 629-629

Bentham Science Publishers

Access to resources Recommend Favorite

5-Azacytidine for the treatment of myelodysplastic syndromes

By Krawczyk Janusz   Keane Niamh   Freeman Ciara Louise   Swords Ronan   O'Dwyer Michael   Giles Francis J  

Expert Opinion on Pharmacotherapy, Vol. 14, Iss. 9, 2013-06 ,pp. : 1255-1268

Informa Healthcare

Access to resources Recommend Favorite

Arsenic trioxide for the treatment of myelodysplastic syndromes

By Vey Norbert  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 3, 2004-03 ,pp. : 613-621

Informa Healthcare

Access to resources Recommend Favorite

Therapeutic spectrum in the treatment of myelodysplastic syndromes

By Hofmann Wolf-K   Baldus Claudia   Uharek Lutz   Thiel Eckhard  

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 12, 2004-12 ,pp. : 2451-2458

Informa Healthcare

Access to resources Recommend Favorite